ALX Oncology (ALXO) Expected to Announce Earnings on Friday

ALX Oncology (NASDAQ:ALXO) is expected to be posting its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect ALX Oncology to post earnings of ($0.38) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 8:30 AM ET.

ALX Oncology Price Performance

NASDAQ ALXO traded down $0.15 during trading on Friday, reaching $2.45. 497,699 shares of the company traded hands, compared to its average volume of 911,652. ALX Oncology has a 1-year low of $0.40 and a 1-year high of $2.66. The company has a market cap of $132.84 million, a price-to-earnings ratio of -1.21 and a beta of 0.51. The stock’s 50 day moving average price is $1.61 and its two-hundred day moving average price is $1.44. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.40 and a current ratio of 2.40.

Insider Transactions at ALX Oncology

In other news, Director Corey S. Goodman bought 3,184,713 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were purchased at an average price of $1.57 per share, for a total transaction of $4,999,999.41. Following the purchase, the director owned 8,453,038 shares of the company’s stock, valued at approximately $13,271,269.66. The trade was a 60.45% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 21.00% of the company’s stock.

Institutional Trading of ALX Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its position in shares of ALX Oncology by 157.2% in the fourth quarter. Renaissance Technologies LLC now owns 423,099 shares of the company’s stock worth $478,000 after purchasing an additional 258,600 shares in the last quarter. Acadian Asset Management LLC increased its stake in ALX Oncology by 16.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after buying an additional 186,883 shares during the last quarter. Two Sigma Investments LP increased its stake in ALX Oncology by 26.9% in the 3rd quarter. Two Sigma Investments LP now owns 606,671 shares of the company’s stock valued at $1,110,000 after buying an additional 128,737 shares during the last quarter. Ameriprise Financial Inc. bought a new stake in ALX Oncology during the 3rd quarter worth about $1,195,000. Finally, State Street Corp boosted its stake in shares of ALX Oncology by 11.0% during the 4th quarter. State Street Corp now owns 124,228 shares of the company’s stock worth $140,000 after buying an additional 12,300 shares during the last quarter. 97.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ALXO has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ALX Oncology in a research note on Wednesday, January 21st. Jefferies Financial Group started coverage on shares of ALX Oncology in a report on Thursday, November 13th. They set a “buy” rating and a $4.00 price objective for the company. Piper Sandler boosted their price objective on ALX Oncology from $3.00 to $4.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Wall Street Zen raised ALX Oncology from a “sell” rating to a “hold” rating in a report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $2.50.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.